Heart transplantation contraindications: Difference between revisions
Jump to navigation
Jump to search
Ifrah Fatima (talk | contribs) No edit summary |
Ifrah Fatima (talk | contribs) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 4: | Line 4: | ||
'''Editor(s)-in-Chief:''' [[C. Michael Gibson, M.S., M.D.]]; '''Associate Editor-In-Chief:''' {{CZ}}{{IF}} | '''Editor(s)-in-Chief:''' [[C. Michael Gibson, M.S., M.D.]]; '''Associate Editor-In-Chief:''' {{CZ}}{{IF}} | ||
=Overview | =Overview= | ||
Contraindications to cardiac transplantation include any multisystem/systemic or life-shortening disease with a life expectancy of less than years, despite a [[heart transplant]]. Other factors that may be potential contraindications to be considered are- age, obesity, cancer, diabetes, renal dysfunction, peripheral vascular disease, infections, and substance abuse. | Contraindications to cardiac transplantation include any [[Multisystem organ failure|multisystem]]/systemic or life-shortening disease with a life expectancy of less than years, despite a [[heart transplant]]. Other factors that may be potential contraindications to be considered are- [[Ageing|age]], [[obesity]], [[cancer]], [[diabetes]], [[Renal insufficiency|renal dysfunction]], [[peripheral vascular disease]], [[Infection|infections]], and [[Substance abuse|substance abuse.]] | ||
==Contraindications== | ==Contraindications== | ||
| Line 18: | Line 18: | ||
**Irreversible [[renal]] or [[Hepatic failure|hepatic dysfunction]] | **Irreversible [[renal]] or [[Hepatic failure|hepatic dysfunction]] | ||
**Significant [[obstructive pulmonary disease]] | **Significant [[obstructive pulmonary disease]] | ||
*Fixed or irreversible [[pulmonary hypertension]] | *Fixed or irreversible [[pulmonary hypertension]] defined by the following findings- | ||
**Pulmonary artery systolic pressure >60 mm Hg | **Pulmonary artery systolic pressure >60 mm Hg | ||
**Mean transpulmonary gradient >15 mm Hg | **Mean transpulmonary gradient >15 mm Hg | ||
| Line 26: | Line 26: | ||
<ref name="MehraCanter2016">{{cite journal|last1=Mehra|first1=Mandeep R.|last2=Canter|first2=Charles E.|last3=Hannan|first3=Margaret M.|last4=Semigran|first4=Marc J.|last5=Uber|first5=Patricia A.|last6=Baran|first6=David A.|last7=Danziger-Isakov|first7=Lara|last8=Kirklin|first8=James K.|last9=Kirk|first9=Richard|last10=Kushwaha|first10=Sudhir S.|last11=Lund|first11=Lars H.|last12=Potena|first12=Luciano|last13=Ross|first13=Heather J.|last14=Taylor|first14=David O.|last15=Verschuuren|first15=Erik A.M.|last16=Zuckermann|first16=Andreas|title=The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update|journal=The Journal of Heart and Lung Transplantation|volume=35|issue=1|year=2016|pages=1–23|issn=10532498|doi=10.1016/j.healun.2015.10.023}}</ref> | <ref name="MehraCanter2016">{{cite journal|last1=Mehra|first1=Mandeep R.|last2=Canter|first2=Charles E.|last3=Hannan|first3=Margaret M.|last4=Semigran|first4=Marc J.|last5=Uber|first5=Patricia A.|last6=Baran|first6=David A.|last7=Danziger-Isakov|first7=Lara|last8=Kirklin|first8=James K.|last9=Kirk|first9=Richard|last10=Kushwaha|first10=Sudhir S.|last11=Lund|first11=Lars H.|last12=Potena|first12=Luciano|last13=Ross|first13=Heather J.|last14=Taylor|first14=David O.|last15=Verschuuren|first15=Erik A.M.|last16=Zuckermann|first16=Andreas|title=The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update|journal=The Journal of Heart and Lung Transplantation|volume=35|issue=1|year=2016|pages=1–23|issn=10532498|doi=10.1016/j.healun.2015.10.023}}</ref> | ||
*'''Age''' - Patients are considered for cardiac transplant if they are < 70 years of age; or carefully selected patients over age 70. | *'''[[Age]]''' - Patients are considered for cardiac transplant if they are < 70 years of age; or carefully selected patients over age 70. | ||
* '''Obesity'''- [[Body mass index|BMI]] > 35 kg/m 2 is associated with a worse outcome. | * '''[[Obesity]]'''- [[Body mass index|BMI]] > 35 kg/m 2 is associated with a worse outcome. | ||
* '''Cancer'''- Careful assessment of each [[neoplasm]] with a collaboration with oncology specialists to stratify each patient must be done. <ref name="pmid19195521">{{cite journal| author=Kellerman L, Neugut A, Burke B, Mancini D| title=Comparison of the incidence of de novo solid malignancies after heart transplantation to that in the general population. | journal=Am J Cardiol | year= 2009 | volume= 103 | issue= 4 | pages= 562-6 | pmid=19195521 | doi=10.1016/j.amjcard.2008.10.026 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19195521 }} </ref> | * '''[[Cancer]]'''- Careful assessment of each [[neoplasm]] with a collaboration with oncology specialists to stratify each patient must be done. <ref name="pmid19195521">{{cite journal| author=Kellerman L, Neugut A, Burke B, Mancini D| title=Comparison of the incidence of de novo solid malignancies after heart transplantation to that in the general population. | journal=Am J Cardiol | year= 2009 | volume= 103 | issue= 4 | pages= 562-6 | pmid=19195521 | doi=10.1016/j.amjcard.2008.10.026 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19195521 }} </ref> | ||
* '''Diabetes'''- End-organ damage and persistent poor [[Glycemic Targets in Diabetes|glycemic]] control ([[glycosylated hemoglobin]] [<nowiki/>[[Glycosylated hemoglobin|HbA 1c]]] > 7.5% or 58 mmol/mol) are relative contraindications | * '''[[Diabetes]]'''- End-organ damage and persistent poor [[Glycemic Targets in Diabetes|glycemic]] control ([[glycosylated hemoglobin]] [<nowiki/>[[Glycosylated hemoglobin|HbA 1c]]] > 7.5% or 58 mmol/mol) are relative contraindications | ||
* '''Renal dysfunction'''- Irreversible [[renal dysfunction]] ( [[eGFR]] < 30 ml/min/1.73 m 2) is a relative contraindication | * '''[[Renal insufficiency|Renal dysfunction]]'''- Irreversible [[renal dysfunction]] ( [[eGFR]] < 30 ml/min/1.73 m 2) is a relative contraindication | ||
* '''Peripheral vascular disease'''- Clinically severe symptomatic [[cerebrovascular disease]] may be considered a contraindication. | * '''[[Peripheral vascular disease]]'''- Clinically severe symptomatic [[cerebrovascular disease]] may be considered a contraindication. | ||
* '''Infections'''- Use of [[Immunosuppressive therapy|immunosuppressive]] therapy post-transplantation may cause a flare up of active [[Infection|infections]]. | * '''[[Infection|Infections]]'''- Use of [[Immunosuppressive therapy|immunosuppressive]] therapy post-transplantation may cause a flare up of active [[Infection|infections]]. | ||
**[[Human Immunodeficiency Virus (HIV)|Human immunodeficiency viral (HIV) infection]] | **[[Human Immunodeficiency Virus (HIV)|Human immunodeficiency viral (HIV) infection]] | ||
**[[Chagas disease]] | **[[Chagas disease]] | ||
Latest revision as of 00:44, 10 July 2020
|
Heart transplantation Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Heart transplantation contraindications On the Web |
|
American Roentgen Ray Society Images of Heart transplantation contraindications |
|
Risk calculators and risk factors for Heart transplantation contraindications |
Editor(s)-in-Chief: C. Michael Gibson, M.S., M.D.; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [1]Ifrah Fatima, M.B.B.S[2]
Overview
Contraindications to cardiac transplantation include any multisystem/systemic or life-shortening disease with a life expectancy of less than years, despite a heart transplant. Other factors that may be potential contraindications to be considered are- age, obesity, cancer, diabetes, renal dysfunction, peripheral vascular disease, infections, and substance abuse.
Contraindications
Absolute Contraindications
- Systemic illness with a life expectancy of less than 2 years despite HT, including
- Active or recent solid organ or blood malignancy in the last 5 years
- AIDS complicated by frequent opportunistic infections
- Active diseases with multisystem involvement like- systemic lupus erythematosus, sarcoidosis, or amyloidosis
- Irreversible renal or hepatic dysfunction
- Significant obstructive pulmonary disease
- Fixed or irreversible pulmonary hypertension defined by the following findings-
- Pulmonary artery systolic pressure >60 mm Hg
- Mean transpulmonary gradient >15 mm Hg
- Pulmonary vascular resistance >6 Wood units
Relative Contraindications due to associated comorbidities
- Age - Patients are considered for cardiac transplant if they are < 70 years of age; or carefully selected patients over age 70.
- Obesity- BMI > 35 kg/m 2 is associated with a worse outcome.
- Cancer- Careful assessment of each neoplasm with a collaboration with oncology specialists to stratify each patient must be done. [3]
- Diabetes- End-organ damage and persistent poor glycemic control (glycosylated hemoglobin [HbA 1c] > 7.5% or 58 mmol/mol) are relative contraindications
- Renal dysfunction- Irreversible renal dysfunction ( eGFR < 30 ml/min/1.73 m 2) is a relative contraindication
- Peripheral vascular disease- Clinically severe symptomatic cerebrovascular disease may be considered a contraindication.
- Infections- Use of immunosuppressive therapy post-transplantation may cause a flare up of active infections.
- Human immunodeficiency viral (HIV) infection
- Chagas disease
- Tuberculosis
- Hepatitis B and C viral (HBV and HCV) infections
- Tobacco use- Active tobacco smoking is a relative contraindication.
- Substance Abuse- Active substance abusers (including alcohol) cannot receive a heart transplant.
- Psychosocial evaluation- Lack of social support of presence of cognitive disability are relative contraindications.
References
- ↑ Mancini, Donna; Lietz, Katherine (2010). "Selection of Cardiac Transplantation Candidates in 2010". Circulation. 122 (2): 173–183. doi:10.1161/CIRCULATIONAHA.109.858076. ISSN 0009-7322.
- ↑ Mehra, Mandeep R.; Canter, Charles E.; Hannan, Margaret M.; Semigran, Marc J.; Uber, Patricia A.; Baran, David A.; Danziger-Isakov, Lara; Kirklin, James K.; Kirk, Richard; Kushwaha, Sudhir S.; Lund, Lars H.; Potena, Luciano; Ross, Heather J.; Taylor, David O.; Verschuuren, Erik A.M.; Zuckermann, Andreas (2016). "The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update". The Journal of Heart and Lung Transplantation. 35 (1): 1–23. doi:10.1016/j.healun.2015.10.023. ISSN 1053-2498.
- ↑ Kellerman L, Neugut A, Burke B, Mancini D (2009). "Comparison of the incidence of de novo solid malignancies after heart transplantation to that in the general population". Am J Cardiol. 103 (4): 562–6. doi:10.1016/j.amjcard.2008.10.026. PMID 19195521.